



MONTHLY REPORT AND FACTSHEET FOR MARCH 2013

NET ASSET VALUE

Net Assets: \$13.5 millions

NAV/Share: \$37.94


ASSET ALLOCATION

India: 99%

Cash: 1%


PERFORMANCE (net of fees and charges)

Period	Fund %	Benchmark %
One Month	1.1	-0.1
Year-to-date	-1.6	-3.1
One Year	-7.0	0.5
Three Years	-14.9	-10.4



Sources: CACEIS: NAV to NAV in \$; NSE India: S&P CNX defty

INDUSTRY CONCENTRATION MARCH 31



Top Ten Holdings %

HDFC Bank	8.5
Pidilite Inds.	7.2
Nestle India	7.0
Balkrishna Inds.	5.9
ICICI Bank	5.7
Infosys	5.5
TCS	5.4
Kotak Bank	5.3
ONGC	4.7
Torrent Pharma	4.7
Total	59.9
Number of Holdings	24
% Invested in Nifty	56.9

FUND INFORMATION

Investment Objective:	Long-term growth through investing in listed companies in India and neighbouring countries
Benchmark:	S&P CNX "NIFTY" Index in US Dollars
Listings:	NYSE Euronext Fund Service, Amsterdam The London Stock Exchange
Managed by::	Himalayan Fund N.V.
Administrator:	Caceis Netherlands NV
London Broker:	Arden Partners plc
Base Currency:	USD
Inception Date:	June 1990
Investment Advisory Fee:	1.5%
Share Type:	Accumulation

OPERATIONAL DETAILS

Valuation:	Weekly	Dealing:	Euronext: Weekly (NAV) LSE: Daily (bid/offer)
Subscription Fee:	0.35% (to Fund)(Euronext)	Redemption Fee:	0.35% (to Fund)(Euronext)
ISIN Code:	NL0000464154	Sedol	0454038-GB
LSE TMID	HYF	Website:	www.himalayanfund.nl

COMMENTARY

Market Context:

In March, the MSCI World index added 1.6% as the US (+3.6%) and Japan (+4%), in particular, advanced strongly. Europe (-0.6%) was set back by the chaotic election results in Italy (-5%) and Asia ex-Japan went soft as well (-2.3%). India largely sat on the fence, with the Nifty moving only -0.1% in the month in US dollar terms.

Performance:

The portfolio gained 1.1% in March, out-performing its benchmark by 1.2% but notably moving in the opposite direction to the underlying market. The Nifty dropped 10 points in the month, with sharp swings from week to week. Two stocks contributed significant points on the upside: HDFC and ITC, while two subtracted: Reliance Industries and Bharti Airtel.

We got a strong boost from our Healthcare exposure, as Lupin (+7.6%), Wockhardt (+6.1%) and Torrent Pharma (+3.7%) all moved up as the sector continued to draw funds. Our best performing stock was Pidilite Industries which added 9.5%. Next came IGL and Balkrishna which both added 8.5%. IGL is expected to benefit from an imminent Supreme Court judgment in its favour. Balkrishna should benefit from currency movements to boost its international revenues. Bajaj Auto was our biggest loser, down 8.7%; Reliance was also out of favour, dropping 4.9%. IDFC lost 3.7% and Nestle dropped 3.5% on fears that its valuation was outstripping its revenue growth potential.

We added to our initial position in Wockhardt Pharmaceuticals where we believe the earnings momentum is strong.

Outlook:

Sentiment was largely stable during March as investors accepted the reality of sustained commitment to fiscal consolidation while the Finance Minister strives to break through bureaucratic obstructions to reviving public sector investment. Meanwhile, the outlook for inflation and the current account deficit has improved measurably due to softening prices of gold and crude oil. Moderating inflation is smoothing the path for monetary easing, so the market is now looking to another policy rate cut in early May, in the midst of the Q4FY13 results season.

Please note that the value of investments and the income derived from them may fluctuate and an investor may not receive back the amount originally invested. Past performance is not necessarily indicative of future performance and the value and any income arising from this fund may go down as well as up. Where an investment is denominated in a currency other than your base currency, exchange rates may have an adverse effect on the value or income of that investment.